
The panel discusses their potential treatment approaches for the presented patient case and how they select patients with relapsed/refractory MM for teclistamab and optimally sequence therapies.

Your AI-Trained Oncology Knowledge Connection!


The panel discusses their potential treatment approaches for the presented patient case and how they select patients with relapsed/refractory MM for teclistamab and optimally sequence therapies.

Jack Khouri, MD, presents the case of a 68-year-old patient with relapsed/refractory multiple myeloma and extramedullary disease treated with teclistamab.

Before closing out their discussion on multiple myeloma management, panelists reflect on real-world clinical practice perspectives on treatment with bispecifics.

A review of novel treatment modalities for relapsed/refractory multiple myeloma, with a focus on selecting and sequencing bispecific antibodies and CAR T-cell therapies.

Expert panelists center discussion on a final patient case to review the identification and management of relapsed/refractory multiple myeloma.

Expert perspectives on selection of induction therapy for patients with transplant-ineligible newly diagnosed multiple myeloma.

Panelists move on to review a patient case of transplant-ineligible newly diagnosed multiple myeloma and highlight clinical workup strategies.

A focused discussion on navigating the treatment armamentarium for patients with transplant-eligible newly diagnosed multiple myeloma.

Centering discussion on a patient case of transplant-eligible newly diagnosed multiple myeloma, expert panelists consider optimal workup and management strategies.